Background: Peripheral blood lymphocyte (PBL) analysis by flow cytometry has been inconsistently reported as an adjunctive method for diagnosing acute kidney transplant rejection. However, there is good evidence that lymphocytes infiltrating renal grafts differ from those found at the peripheral level. We hypothesized that the study of aspiration biopsy samples in conjunction with PBL by flow cytometry would enable us to diagnose acute rejection crisis reliably.
Methods: Lymphocytes from PBL and aspiration biopsies of kidney transplant patients were analyzed. Fifty-one stable patients, rejection-free for the first 6 months, were studied on day 7 and day 30 after transplantation and were compared with 32 patients with 40 acute rejection episodes.
Results: Significant differences were observed for several lymphocyte subpopulations on aspiration biopsy samples comparing stable patients with rejection patients. In contrast, PBL analysis was not helpful in differentiating the two groups of patients. By combining the expression of several activation markers inside the graft with CD3DR and CD3CD25 aspiration biopsy to peripheral blood ratios, we obtained very good values for sensitivity and specificity-83.9% and 90.5%, respectively. The positive predictive value for rejection among dysfunctional grafts reached 85.8%.
Conclusions: Flow cytometry study of aspiration biopsy samples of kidney transplant patients is a reliable and powerful method to diagnose acute rejection episodes, although it is needed to consider several lymphocyte phenotypes; cytofluorometric analysis of PBL is important because it provides graft-infiltrating cell to peripheral blood lymphocyte ratios. This safe and rapid test may significantly improve the management of kidney transplant patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/00007890-199707150-00018 | DOI Listing |
Clin Kidney J
January 2025
Sydney School of Public Health, University of Sydney, Sydney, NSW, Australia.
Background: The symptoms, comorbidities and treatment burden associated with chronic kidney disease (CKD) can be debilitating and limit life participation in patients with CKD not requiring kidney replacement therapy (KRT). The aim of this study was to identify the characteristics, content and psychometric properties of patient-reported outcome measures (PROMs) used to assess life participation in patients with CKD.
Methods: We searched MEDLINE, Embase, PsycINFO and CINAHL from database inception to February 2023 for all studies that reported life participation in patients with CKD (stages 1-5 not requiring kidney replacement therapy).
Eur Urol Open Sci
January 2025
Department of Urology, Hospital Universitari de Bellvitge, Barcelona, Spain.
The indication for kidney transplantation over a urinary diversion (UD) for patients with severe lower urinary tract dysfunction and end-stage renal disease is a controversial issue. Thanks to advances in robot-assisted kidney transplant (RAKT) programs, the boundaries are being pushed further. We present the first RAKT series reported for patients undergoing simple cystectomy and UD for benign bladder disease.
View Article and Find Full Text PDFKidney Int Rep
January 2025
Division of Nephrology, Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Introduction: Muscles are crucial for daily activities, and kidney transplant recipients (KTRs) often have reduced muscle mass and strength. We aimed to investigate the potential relationship of muscle mass and strength with physical health-related quality of life (HRQoL) in KTRs.
Methods: Data from the TransplantLines Biobank and Cohort Studies were used.
Kidney Int Rep
January 2025
Department of Immunology and Immunogenetics, Centre Hospitalier Universitaire de Limoges, Limoges, France.
Kidney Int Rep
January 2025
Division of Nephrology, Department of Medicine, University of California San Francisco, California, USA.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!